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ABSTRACT
Peptides are remarkably reactive molecules produced by a great variety of species and able to display a number of
functions in uni- and multicellular organisms as mediators, agonists and regulating substances. Some of them exert
cytotoxic effects on cells other than those that produced them, and may have a role in controlling subpopulations
and protecting certain species or cell types. Presently, we focus on antifungal and antitumor peptides and discuss
a few models in which specific sequences and structures exerted direct inhibitory effects or stimulated a protective
immune response. The killer peptide, deduced from an antiidiotypic antibody, with several antimicrobial activities and
other Ig-derived peptides with cytotoxic activities including antitumor effects, are models studied in vitro and in vivo.
Peptide 10 from gp43 of P. brasiliensis (P10) and the vaccine perspective against paracoccidioidomycosis is another
topic illustrating the protective effect in vivo against a pathogenic fungus. The cationic antimicrobial peptides with
antitumor activities are mostly reviewed here. Local treatment of murine melanoma by the peptide gomesin is another
model studied at the Experimental Oncology Unit of UNIFESP.
Key words: bioactive peptides, Paracoccidioides brasiliensis, tumor cells, killer peptide, melanoma, apoptosis.
INTRODUCTION
Bioactive peptides arise from proteins by the action of
peptidases or are chemically synthesized based on cer-
tain templates of natural sequences that have been se-
lected by a variety of screening methods. Peptides can
be designed aiming at enhanced functional activity by
using amino acid substitutions and chemical modifica-
tion. Owing to their great diversity of binding properties,
peptides can play roles of biochemical reagents, phar-
macological drugs, hormones, antibiotics, vaccines and
mediators of neural and immunological signaling. Pep-
tides interact with membrane structures, are specifically
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recognized by cell surface receptors or act as ligands in-
teracting with intracellular compounds and subcellular
structures. Peptides can include epitopes recognized by
antibodies and TCRs, and those called protective epi-
topes elicit a protective immune response. On focusing
the actual fungal and tumor models, peptides that display
direct cytotoxicity on target cells or elicit a protective
immune response in animals experimentally infected or
challenged with tumor cells have been investigated.
ANTIFUNGAL PEPTIDES
During the past decades, an increase in the incidence of
fungal diseases has been recognized mainly caused by
Candida spp. and filamentous fungi such as Aspergil-
lus spp. (reviewed in Mavor et al. 2005 and Brakhage
2005). To date, there are no licensed fungal vaccines, and
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the use of antimycotics is the only option for the treat-
ment of fungal infections. Currently used antimycotics,
however, frequently have a limited activity spectrum, are
available only in intravenous formulations, favor resis-
tance development, and cause serious side-effects (re-
viewed in François et al. 2005). Thus, the search for
new antifungal therapies is strongly stimulated, and the
use of antifungal peptides is a promising alternative.
Antifungal properties of peptides have been re-
viewed by De Lucca and Walsh (2000). There are 405
peptides with antifungal properties described, compris-
ing linear or cyclic, hydrophobic or amphipathic struc-
tures (http://aps.unmc.edu/AP/main.php).
Their cytotoxicity may involve binding to and dis-
ruption of the membrane (Shai 1995), membrane pene-
tration and interaction with the mitochondria (Helmer-
horst et al. 1999) or pore formation (Bechinger 1997).
Antifungal peptides have been studied in bacteria, fungi,
plants, insects, amphibians and mammals. Relevant ex-
amples are given next.
Syringomycins, syringostatins and syringotoxins
from Pseudomonas syringae are lipodepsipeptides
highly lethal to Candida albicans, Aspergillus and Fu-
sarium species (De Lucca and Walsh 2000, De Lucca
et al. 1999, Sorensen et al. 1996). Glycopeptide cepa-
cidines from Burkholderia cepacia are active against
Candida sp., Aspergillus niger, Fusarium oxysporum
and Cryptococcus neoformans (Lee et al. 1994, Lim et
al. 1994). Antifungal peptidylnucleoside nikkomycins
are produced by Streptomyces tendae, act by inhibiting
chitin biosynthesis and were effective in murine infec-
tions by Coccidioides immitis and Blastomyces dermati-
tidis (Hector et al. 1990). Zeamatin, the 22 kilodal-
ton (kDa) peptide produced by Zea mays, permeabi-
lizes the fungal membrane and kills C. albicans with
a minimal inhibitory concentration (MIC) of 0.5 μg/ml
(Roberts and Selitrennikoff 1991). Cecropins from the
silk moth Hyalopora cecropia are linear, lytic peptides
effective against germinating conidia of F. oxysporum
and A. fumigatus (De Lucca et al. 1998). Both the L-
and D-isomeric forms of cecropin B were fungicidal (De
Lucca et al. 2000). Drosomycin is a 44 amino acids (aa)
inducible peptide active against F. oxysporum (Lemaitre
et al. 1997). There is no evidence of adaptive protein
evolution in the drosomycin genes, suggesting that they
do not coevolve with pathogens (Jiggins and Kim 2005).
In contrast, antimicrobial peptides (AMPs) appear to un-
dergo a rapid adaptive evolution in vertebrates. In frogs,
each species produces 10-20 AMPs that differ in size,
sequence and specificity, and this rapid diversification is
driven by evolutionary selection (Duda et al. 2002). Der-
maseptins, produced by Phyllomedusa sauvagii, a South
American frog, are lysine-rich linear peptides fungici-
dal for A. flavus, A. fumigatus and F. oxysporum (Mor
et al. 1994). Magainins are antifungal peptides pro-
duced by the African frog Xenopus laevis (De Lucca and
Walsh 2000). They are not hemolytic and inhibit Can-
dida albicans (Zasloff 1987). Plant [DmAMP1 from
dahlia (Dahlia merckii), RsAFP2 from radish (Raphanus
sativus), HsAFP1 from coral bells (Heuchera sangui-
nea), Psd1 from pea (Pisum sativum), MsDef1 from al-
falfa (Medicago sativa) and MtDef2 from barrel medic
(Medicago truncatula)], insects (Termicin from the ter-
mite Pseudacanthotermes spiniger, Drosomycin from
the fruitfly Drosophila melanogaster, Heliomicin from
the tobacco budworm Heliothis virescens) and human [β-
defensin 1 (HBD1), β-defensin 2 (HBD2), β-defensin
3 (HBD3)] defensins showed antifungal properties (re-
viewed in Aerts et al. 2008). Although there are no clear
similarities in the mode of action of these defensins, the
presence of sphingolipid glucosyl ceramide (GlcCer) in
fungal membranes seems to play a central role in the ac-
tion of some defensins (Thevissen et al. 2004). Only
Psd1 was internalized in the fungal cell, affecting the
normal progression of the cell cycle (Lobo et al. 2007),
and it is possible that the other defensins stay outside the
cell inducing fungal cell death after interaction with their
target (e.g. sphingolipids) and modulation of intracellu-
lar signaling cascades (Aerts et al. 2008). RsAFP2 was
also effective in an in vivo prophylactic model of murine
candidiasis (Tavares et al. 2008).
β-Defensins include porcine cationic, cysteine-rich
protegrins which inhibited C. albicans (Cho et al. 1998).
Gomesin, a cationic AMP isolated from the hemocytes
of the unchallenged Brazilian spider Acanthoscurria
gomesiana (Silva et al. 2000), is structurally related to
protegrins and exerts microbicidal activity against fila-
mentous fungi, yeast and parasites. Gomesin bound to
the surface of Cryptococcus neoformans, resulting in cell
death by membrane permeabilization. Fungal growth, in
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the presence of the peptide, induced a decrease in cap-
sule expression, rendering cells more susceptible to brain
phagocytes and, in association with fluconazole, in con-
centrations with low antimicrobial activity (0.1–1μM),
inhibited fungal growth and enhanced the antimicrobial
activity of brain phagocytes (Barbosa et al. 2007). One
of the models described in the present review is that of
gomesin cytotoxicity in murine and human tumor cells
(Rodrigues et al. 2008).
Among the antifungal peptides produced by fungi,
the echinocandins interfere with the cell wall biosyn-
thesis (Denning 1997) and the pneumocandins, aculea-
cins, WF11899, and mulundocandins have a modified
echinocandin B peptide core (Debono and Gordee 1994,
Kurtz and Douglas 1997). Echinocandins are produced
by Aspergillus nidulans and A. rugulosus and are effec-
tive against Candida (MIC = 0.6μg/ml for echinocandin
B and C. albicans) (reviewed in De Lucca and Walsh
2000). Clinical trials have started with molecules of
the echinocandin group, VER-002, FK463 and caspo-
fungin (MK-0991) modified for increased solubility and
active against Candida spp. and Aspergillus spp. V-
echinocandin and FK463 were effective in the treatment
of esophageal candidiasis, the latter in AIDs patients
(reviewed in De Lucca and Walsh 2000). Clinical tri-
als with caspofungin (derived from pneumocandin), a
drug that inhibits β-1,3 D-glucan synthase, have shown
excellent results in the treatment of Candida infections
and invasive aspergillosis refractory to other antifungal
agents (i.e., conventional or lipid formulations of ampho-
tericin B and/or itraconazole). Aureobasidins are pro-
duced by Aureobasidium pullulans, interfere with sphin-
golipid synthesis and are effective against murine can-
didiasis (Nageic et al. 1997, Takesako et al. 1993).
KILLER TOXINS AND KILLER PEPTIDES
Killer yeasts secrete killer toxins that target suscepti-
ble cells in a two-step receptor-mediated manner. They
bind to cell wall receptors and translocate to the plasma
membrane. They can then interact with secondary
receptors or enter susceptible cells to exert a cytoci-
dal effect (Magliani et al. 1997, Schmitt and Breinig
2006). β-1,6 Glucan, α-1,3 mannoprotein and β-1,3
glucan are possible receptors, the latter for killer toxins
from species of Pichia and Williopsis. Killer toxins kill
susceptible cells by various mechanisms, including the
induction of cation-selective ion channels in the plasma
membrane, interference in the cell cycle (G1, G1/S, S
arrest), chromosomal DNA synthesis and anticodon nu-
clease (Schmitt and Breinig 2006, Santos and Marquina
2004, Jablonowski and Schaffrath 2007, Klassen et al.
2004). Killer toxins can induce apoptosis mediated by
yeast caspase Yca1p, characterized by DNA fragmenta-
tion, and phosphatidylserine external membrane expres-
sion. This could be a general cell death mechanism un-
der natural environmental conditions (Paluszynski et al.
2007, Schmitt and Reiter 2008).
The direct use of killer toxins in antifungal ther-
apy was discouraged owing to some of their proper-
ties. They are generally heat-labile, protease-sensitive
and act within a narrow pH and temperature range. They
are antigenic and toxic, as shown for Pichia anomala
killer toxin (Pettoello-Mantovani et al. 1995). To over-
come these pitfalls of a potential therapeutic agent, im-
munological derivatives were generated on the basis of
the idiotypic network that mimicked the toxic effect of
P. anomala killer toxin (Polonelli et al. 1991). Killer
antibodies with the internal image of the active site of
a killer toxin, which acted as antibiotics, were then ob-
tained. They exerted significant therapeutic effects in
experimental models of candidiasis, aspergillosis and
pneumocystosis.
Toxic effects were also obtained with single chain
variable fragment (scFv) preparations and they were fur-
ther examined by synthesizing overlapping decapeptides
which correspond to the light chain of antibodies (VL)and heavy chain of antibodies (VH) regions. These re-gions include the complementary determining regions
(CDRs) that were tested in vitro against C. albicans.
Several peptides were active and one of them, corres-
ponding to the framework sequence with the final three
amino acids belonging to VL CDR1, was selected. Itwas very cytotoxic and the substitution of the N-ter-
minal glutamic acid by alanine generated a peptide with
the AKVTMTCSAS sequence that was several times
more active and was called killer peptide (KP). The KP
interacted with β-glucan and this binding was inhibited
in a dose dependent manner by laminarin (Polonelli et
al. 2003). The peptide was as active as the killer an-
tibody against a number of microbial pathogens in ad-
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dition to C. albicans, and was effective even in normal
and immunocompromised animals against vaginal and
systemic candidiasis (Polonelli et al. 2003), dissemi-
nated cryptococcosis (Cenci et al. 2004) and paracoc-
cidioidomycosis (Travassos et al. 2004a). The KP is
very stable forming dimers in non-reducing conditions
without loss of activity (Magliani et al. 2004a, b).
The remarkable cytotoxicity of KP was also exam-
ined by electron microscopy. C. albicans cells treated
with KP showed important internal alterations, includ-
ing cell wall swelling with middle electron-dense re-
gion, collapse of the plasma membrane, condensation
and fragmentation of nuclear material, and alteration of
mitochondria structure (Fig. 1A). In a dividing cell with
a big vacuole and chromatin condensation and fragmen-
tation, cellular alterations were seen beyond the septum
separating both cells, with the daughter cell already af-
fected by the KP showing an altered cell wall (Fig. 1B).
A MODEL OF DIRECT ANTIFUNGAL EFFECT
OF A PEPTIDE
Glucans, chitin and mannoproteins, in addition to plasma
membrane sterols, are natural targets of antifungal drugs.
Additional targets are ceramide monohexosides, ubiqui-
tously present on the fungal cell wall and displaying
several roles in fungal cells (Nimrichter et al. 2008). In
C. neoformans (Rodrigues et al. 2000), C. albicans and
Pseudallescheria boydii, these glycolipids were identi-
fied as targets of human antibodies that inhibited fun-
gal growth. Other targets are melanin, adhesion factors,
and cell wall enzymes. The killer decapeptide (KP) de-
scribed above was synthesized and engineered demon-
strating a strong candidacidal activity in vitro and curing
rat vaginal infections caused by fluconazole-susceptible
and -resistant C. albicans strains (Polonelli et al. 2003).
The fungicidal activity of KP in vitro against P. brasi-
liensis and its therapeutic activity in vivo have been re-
ported (Travassos et al. 2004a).
Paracoccidioidomycosis (PCM) is the prevalent
systemic mycosis in South America with most reported
cases in Brazil. It is a major cause of disability and
death among young adult rural workers. Sequels are fre-
quent. The evolution of the disease and the mortality
burden are influenced by the socio-economic status of
the patients. Although long periods of antifungal ther-
Fig. 1 – Electron micrographs showing the cytotoxic effects of the
killer peptide (KP) on Candida albicans. (A) Normal untreated or
treated with the inactive scrambled peptide C. albicans yeast cell (left)
as compared with the KP-treated yeast cell (right). Major alterations
can be seen as the swelling of the cell wall, plasma membrane collapse,
chromatin condensation and nuclear fragmentation. (B) An elongated
C. albicans cell with a budding cell, both affected by KP treatment.
The same alterations as in (A) are seen with nuclear fragmentation and
cytoplasmic blebs invading the daughter cells beyond the septum.
apy with itraconazole, amphotericin or sulfamethoxa-
zole/trimethoprim are used in clinical practice, relapses
are a significant unsolved problem (Travassos et al.
2008b). Vaccination against PCM is now a prospective
goal after P10, and four other peptides derived from the
major diagnostic antigen gp43 were found to be promis-
cuously presented by several human leukocyte antigens
DR, MHC class II molecules (HLA-DR) (Iwai et al.
2003). Such a vaccine could function as an adjuvant
to chemotherapy significantly reducing the time of treat-
ment (Travassos et al. 2008a, b).
Wide-spectrum antimicrobial peptides, such as KP,
might also be considered as an alternative adjuvant to
chemotherapy, and the projected peptide immunother-
apy to shorten the time of treatment and as another op-
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tion in cases of anergy and drug resistance. Multiply-
budding yeast cells of P. brasiliensis had their viability
hampered at 39 ng of KP/yeast in distilled water. The
D-isomeric form of KP was also active. Further, the
decapeptide was therapeutic in B10A mice infected in-
travenously with 3 × 106 cells of P. brasiliensis Pb18
isolate administered intraperitoneally at 3.3 μg/g of
body weight, 1 h after infection and 1 and 2 days later.
With this protocol, no colony forming units (CFUs) were
obtained from lung, spleen and liver after 8 days of fun-
gal challenge in the KP treated animals. In these animals
compared to those injected with the scrambled peptide,
the liver granulomas were smaller and fewer with no
visible fungi. The lungs were less infiltrated with exten-
sive areas of normal alveoli and no visible fungi. Spleens
also were little affected, with no detectable fungi.
It was clear therefore that KP was an effective in-
hibitor of P. brasiliensis in vitro and in vivo (Travassos
et al. 2004a).
It is still not clear whetherα-1,3 glucan, the predom-
inant polysaccharide of yeast forms of P. brasiliensis,
is a target of KP. There is, however, evidence that yeast
forms may have β-glucans at the cell surface. Macro-
phages from pentraxin 3 transgenic (PTX3 Tg) mice
showed improved opsonin-independent phagocytosis of
zymosan particles and yeast forms of P. brasiliensis. In
the case of P. brasiliensis, an enhanced microbicidal
activity accompanied by high production of nitric ox-
ide was observed in macrophages from transgenic mice.
Blockade of dectin-1 receptor for β-1,3 glucan inhib-
ited the phagocytosis of zymosan particles by PTX3 Tg
macrophages, pointing out the relevant role of dectin-1
as the main receptor involved in zymosan and possibly
also of P. brasiliensis uptake (Diniz et al. 2004).
BIOACTIVE PEPTIDES EXPRESSED AS
IMMUNOGLOBULIN ISOLATED CDRs
The discovery by Polonelli et al. (Polonelli et al. 2003,
Magliani et al. 2004a, b) that internal sequences of im-
munoglobulin variable regions may display antibiotic
properties prompted us to investigate the activity of mon-
oclonal antibody (mAb) CDRs tested as synthetic pep-
tides. Immunoglobulins have polymorphic heavy and
light chains and the idiotypic variability is related to
the diversity of the antigen binding site and particularly
to the hypervariable domains called complementarity-
determining regions (CDRs). There are 6 CDRs in both
variable regions of light (VL) and heavy chains (VH)with background variability on each side of the CDRs.
The CDRs are named H1, H2, H3 and L1, L2, L3 in
heavy and light chains, respectively. The framework
sequences between CDRs can be similar or identical.
Although all CDRs are expected to contribute to anti-
gen binding with variable affinity, only the CDR 3 from
VH when tested as an isolated linear or cyclic peptidewas found to have the same specificity of the original
antibody, sharing some of its biological properties. VHCDR3 (H3) peptides with such properties have thus been
called micro (mini) antibodies (Levi et al. 1993, Bour-
geois et al. 1998). They can even compete with the an-
tibody for binding to a certain antigen. The other CDRs
generally do not show a similar reactivity when tested
as isolated peptides.
Recently we showed, in collaboration with Polo-
nelli’s and Ponton’s groups from Parma and Bilbao, re-
spectively, that, independently of the specificity of the
native Ab, CDRs other than H3 may display, with high
frequency, antimicrobial, antiviral and antitumor activ-
ities in a way reminiscent of molecules of early innate
immunity (Litman et al. 2005). The following mAbs
were studied as sources of the CDRs: Ab (mAb C7),
raised against a C. albicans antigen; mouse mAb pc42,
sharing H1 and H2 with mAb C7; and human mAb
HuA, sharing no CDR either with mAb C7 or mAb pc42,
with specificity for difucosylated blood group A. All
mAbs generated CDRs that, represented by synthetic
peptides, showed in vitro, ex vivo and/or in vivo differen-
tial antimicrobial (C. albicans), antiviral (HIV-1) and/or
antitumor activities (Polonelli et al. 2008).
CDRs C7/pc42 H2 and HuA L1 were directly cyto-
toxic for melanoma and HL-60 (human leukemia) cells
causing caspase-dependent apoptosis. H2 peptide ac-
tivity was receptor-mediated in melanoma cells. Both
C7 H2 and HuA L1 peptides in the C-terminal amidated
form were active against lung colonization by melanoma
cells by intravenous injection (i.v.). Peptides were ad-
ministered by intraperitonial injection (i.p.) (250 μg)
every other day for 11 days, starting on the 1st day af-
ter tumor cell challenge. After 22 days and compared
to the untreated control, the number of cancerous nod-
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ules in the lungs of peptide treated animals were very
few. Presumably, even better results could have been
obtained by optimization of the peptide administration
protocol (Polonelli et al. 2008). C7 H3 but not C7/pc42
H2 competed with mAb C7 for binding to phosphatidyl-
choline, the probable ligand of polyreactive C7 (IgM) on
melanoma cells. This CDR (C7 H3) together with the
H3 CDRs of two anti-melanoma mAbs (A4 and A4M),
that competed with the antibodies for binding to mel-
anoma cells, were three examples of micro (mini) anti-
bodies shown in our laboratory (unpublished results).
A PEPTIDE VACCINE AGAINST
PARACOCCIDIOIDOMYCOSIS
The main diagnostic antigen of P. brasiliensis was iden-
tified in our laboratory in 1986 (Puccia et al. 1986; re-
viewed Travassos et al. 2004b). Glycoprotein gp43 re-
acts with 100% sera of patients with paracoccidioido-
mycosis from a vast region of South America, with the
possible exception of sera from certain Western areas.
It elicits an immune response that protects against the
intratracheal challenge by virulent P. brasiliensis yeast
cells. This molecule has been cloned and sequenced
(Cisalpino et al. 1996). Apart from B cell epitopes,
which are beginning to be identified, the gp43 carries
an immunodominant epitope that elicits a predominant
IFN-γ -mediated Th-1 response. It is responsible for
delayed type sensitive (DTH) reactions in infected ani-
mals (Rodrigues and Travassos 1994). The T-CD4+ cell
epitope was mapped to a peptide called P10 with the
QTLIAIHTLAIRYAN sequence, the HTLAIR hexapep-
tide core being essential for priming the immune re-
sponse (Taborda et al. 1998). P10 was as protective
as the gp43 in intratracheal injection (i.t.) challenged
mice, being administered i.p with complete Freund’s ad-
juvant (CFA). The nucleotide sequence encoding P10
was conserved in a number of isolates (Travassos et
al. 2004b).
The T cell epitope in peptide P10 is presented by
major histocompatibility complex (MHC) class II mo-
lecules from three different mouse haplotypes (Taborda
et al. 1998). Promiscuity of P10 was also observed with
different HLA-DR alleles, as this peptide and a derivative
(gp43180-194) without the C-terminal asparagine residue
and with N-terminal lysine bound to nine prevalent
Caucasian HLA-DR molecules (Iwai et al. 2003).
Additional gp43 peptides were also identified using the
TEPITOPE algorithm, which bound promiscuously to
several HLA-DR molecules. As pointed out before
(Travassos et al. 2008a, b) this is an essential property
of a vaccine peptide candidate considering the genetic
diversity of the target immunizable population.
In 29 patients with PCM and submitted to
chemotherapy, 79% of them recognized one peptide se-
lected by the TEPITOPE algorithm. By pooling pep-
tides gp4345-59, gp43106-120, gp43181-195 or P10, and
gp43283-298, the recognition frequency increased to 86%
(Iwai et al. 2007). Overall for 25 Caucasian HLA-DRs,
P10 and neighboring peptides were predicted to bind
(TEPITOPE) to 90% or more of these molecules. Very
few healthy individuals had peripheral blood mononu-
clear cells (PBMC) proliferating with gp43 and even
fewer with gp43 derived peptides. They may have been
exposed to P. brasiliensis on a trip to reserve areas of
the fungus or cross-reacted with related fungal antigens,
possibly also exo-β-1,3-D-glucanases. Site homologous
but unidentical sequences, in comparison with P10, were
found in β-1,3-glucanases from Aspergillus nidulans,
Histoplasma capsulatum, Blastomyces dermatitidis and
Lacazia loboi (a gp43-like protein).
The rationale for a peptide vaccine based on P10
has been discussed recently (Travassos et al. 2008a).
Basically: “Stimulation of an effective IFN-γ -producing
T-helper response can simultaneously trigger the pro-
duction of potentially protective antibodies and the ac-
tivation of CD8+ T cells in addition to activation of
phagocytic cells. In the presence of several immuno-
genic molecules of the fungal agent, stimulation of one
arm of the immune system may alter a state of early or in-
stalled immunosuppression”. Since treatment of fungal
infections and particularly of PCM involves chemothera-
peutic drugs, a peptide vaccine could work as an adjuvant
to reduce the treatment period, which is usually long,
avoid relapses and reverse the potentially lethal anergic
cases. It also could help to treat those cases of fungal
drug resistance.
To tackle the above issues while using experimental
PCM in Balb/c mice, P10 immunization was associated
with chemotherapy in i.t. infected animals using two
protocols. In the first protocol, infected mice were treated
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with P10 and/or a chemotherapeutic drug starting after
48h of infection. In the second protocol, P10 and/or drug
treatment was started after 30 days of infection. It aimed
at reproducing a condition of established infection as in
patients with PCM. The treatment was held for 30 days,
during which groups of mice received i.p. doses of itra-
conazole, fluconazole, ketoconazole, sulfamethoxazole
or trimethoprim-sulfamethoxazole at every 24 h. Am-
photericin B was given at every 48 h. P10 was admin-
istered weekly for 4 weeks, initially in CFA and three
times in incomplete Freund’s adjuvant (Marques et al.
2006).
In all cases, there was an additive protective effect
with the combination of P10 immunization and chemo-
therapy. Animals treated with sulfamethoxazole showed
early protection followed by relapse. Significantly, the
association of sulfamethoxazole and P10 successfully
controlled the infection. In the second protocol, the
fungal burden was examined after 60 and 120 days of
infection. An additive protective effect of P10 immu-
nization and drug treatment was also observed, with 60
to 80% reduction in lung CFUs. Chemotherapy alone
induced a predominant Th-2 response with increased
production of IL-4 and IL-10 detected in lung homo-
genates, whereas P10 vaccination stimulated a Th1 re-
sponse, rich in IFN-γ and IL-12 without suppressing the
Th-2 response (Marques et al. 2006). These are encour-
aging results in short term experiments. It is probable
that an increased protective effect will be obtained in
long term trials in which the animals will have time to
completely recover of the fungal infection.
The condition of anergy was addressed as follows.
Balb/c mice were treated with dexamethasone-21 phos-
phate added to drinking water. Negative DTH with P.
brasiliensis antigen was obtained after 30 days. Im-
munosuppressed mice (n=10), infected with virulent P.
brasiliensis, began to die 10 days after infection, and all
animals were dead after 70 days. Chemotherapy and/or
P10 immunization of immunosuppressed animals was
started 15 days after i.t. infection and all treated animals
survived thereafter. Chemotherapy and P10 immuniza-
tion conferred additive protection. A significant increase
in IL-12 and IFN-γ and decrease of IL-4 and IL-10 were
observed in mice immunized with P10 alone or associ-
ated with antifungal drugs (Marques et al. 2008). These
results suggest that P10 immunization can be protective
in anergic patients.
Delivery of peptides for an efficient immunization
has always been a concern of our group because previous
experiments have always used CFA as an adjuvant. The
following alternatives therefore have been investigated.
Early studies have shown that immunization of
Balb/c mice with a mammalian expression vector (VR-
gp43) carrying the full gene of gp43 with Cytomegalo-
virus (CMV) promoter induced B and T cell-mediated
immune responses which were protective against the i.t.
challenge by virulent P. brasiliensis yeast forms (Pinto
et al. 2000). The cellular immune response in mice im-
munized with VR-gp43 was kept for at least 6 months
after immunization. A similar construction with P10
was made several years later. Immunization with the
P10 minigene in plasmid DNA alone or associated with
a plasmid carrying mIL-12 insert was tested in Balb/c
mice i.t. infected with a virulent isolate (Pb18) of P.
brasiliensis. A significant reduction of fungal burden in
lung, spleen and liver was obtained with production of
IL-12 and IFN-γ and reduction of IL-4 levels in lung
homogenates (G. Rittner et al., unpublished results).
The construction of MAP (multiple antigen pep-
tide) was also tried to deliver a tetravalent antigen con-
taining P10 sequence. MAP-10, or M10, had four equal
LIAIHTLAIRYAN (QT-less P10) chains synthesized on
a branched lysine core. Lymph node cell proliferation
from P10 or M10-sensitized mice was identical with in
vitro stimulation with either P10 or M10. Immunization
with single dose of M10 without adjuvant was protec-
tive with few lung, spleen and liver CFUs and few or
no yeasts in lung histopathological sections (Taborda et
al. 2006).
In Balb/c mice infected i.t. for 30 days, the pro-
tective effect of P10 was tested alone or mixed with
adjuvants: alum, monophosphoryl lipid A or complete
Freund’s adjuvant (Travassos et al. 2008a, b). Unexpect-
edly, P10 administered in phosphate-buffered saline was
most effective with a significant reduction in lung CFUs
with no fungi detected in spleens and livers.
The protective effect of P10 has also been tested
with anti-gp43 mAbs. Anti-gp70 mAbs have been de-
scribed as protective against experimental PCM (Mattos
Grosso et al. 2003). In patients that underwent chemo-
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therapy, both gp43 and gp70 are markers for monitoring
successive treatment and cure through their decreased
antigenemia and specific antibody response (Marques
da Silva et al. 2004, Silva et al. 2004). In the experi-
mental Balb/c model of PCM infection, anti-gp43 mAb
3E effectively reduced the fungal burden and promoted
phagocytosis in vitro (Buissa-Filho et al. 2008). The
recognized epitope in the gp43 was mapped to the
sequence NHVRIPIGYWAV shared with Aspergillus
fumigatus, A. oryzae and B. graminis internal sequences
of β-1,3-glucanases. This peptide could increase the
protective effect of P10 in a possible peptide vaccine
against PCM.
Again, as stressed, we quote our own thought ex-
pressed before (Travassos et al. 2008a): “Short term
protocols (30 to 45 days) have the advantage of allow-
ing repeated experiments to define a certain response.
However, longer periods of treatment and observation
may lead to even more effective results, aiming at ster-
ilization in experimental models with massive infection
loads”.
ANTITUMOR PEPTIDES
Cancer remains as a major source of mortality and
morbidity around the world, despite numerous recent
advances in treatment alternatives. Chemotherapy and,
more recently, biochemotherapy, is still the choice treat-
ment for advanced and metastatic disease (Espinosa et
al. 2003). It is, though, often associated with delete-
rious side effects caused by drug-induced damage to
healthy cells and tissues (Buzaid and Atkins 2001).
Quiescent or slowly proliferating cancer cells are re-
fractory to the cytotoxic effect of drugs interfering with
DNA synthesis (Naumov et al. 2003) and, frequently,
cellular changes affected sensitivity to chemotherapeu-
tic drugs by increased expression of drug-detoxifying
enzymes and/or drug transporters, altered interactions
between the drug and its target, increased ability to re-
pair DNA damage and defects in the apoptotic pathway
(Gatti and Zunino 2005). Development of a new class of
anticancer drugs that lack toxicity to healthy cells and are
unaffected by common mechanisms of resistance would
be a major advance in cancer chemotherapy. In this sense
bioactive peptides, including cationic antimicrobial pep-
tides (CAPs), are promising candidates for antitumor
treatment.
CAPs have been found in all species that have been
tested so far, including bacteria, fungi, plants and ani-
mals, and they probably represent one of the first evolved
forms of defense of eukaryotic cells against pathogens
(Zasloff 2002). An updated list of CAPs can be found
in http://aps.unmc.edu/AP/main.php, with 1,393 entries.
Most CAPs have a broad spectrum of antimicrobial ac-
tivities; only 82 of the listed CAPs were active, however,
against tumor cells.
Despite their diverse origins, antimicrobial pepti-
des have common biophysical parameters, including
small size, positive charge, and amphipathicity, that are
likely important for peptide activity. These molecules
are grouped according to structural characteristics, and
are usually separated in three classes: (1) linear, often
forming alpha-helical structures; (2) cysteine stabilized,
beta-sheet structures; and (3) peptides with one or more
predominant amino acid residues, but variable in struc-
ture (Yount et al. 2006). As stated before, not all CAPs
are able to kill cancer cells, and to date, it has not been
possible to predict an antitumor activity based on the
peptide structure.
The short length and cationic/amphipathic proper-
ties of these molecules enable CAPs to interact and dis-
rupt lipid membranes. Positively charged amino acid
residues, such as lysine and arginine, and hydropho-
bic residues are frequently found in large numbers in
CAPs (Hoskin and Ramamoorthy 2008). The high ex-
pression of anionic molecules, such as phosphatidylser-
ine in the outer membrane leaflet of human tumor cells
(Utsugi et al. 1991, Dobrzynska et al. 2005), as well
as O-glycosylated mucins (Yoon et al. 1996) on can-
cer cell membranes, account for the net negative charge
of these cells and their electrostatic interactions with
cationic CAPs. In the case of magainin peptides, the
cytotoxic activity for tumor cells was abolished by elim-
inating the electrical gradient across the plasma mem-
brane. Apparently, the cellular potential is critical for
peptide channel formation in tumor cell membranes and
could determine the selective killing of tumor cells by
CAPs (Cruciani et al. 1991). The interaction between
CAPs and normal cells is not favored because of the
overall neutral charge conferred by the zwitterionic
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major membrane components, such as sphingomyelin,
phosphatidylethanolamine and phosphatidylcholine
(Zachowski 1993).
CAPs interaction with cancer cell membranes is not
mediated by receptors, since D-amino acid peptide ana-
logues displayed an activity similar to the all-L-amino
acid peptide (Rodrigues et al. 2008, Hetru et al. 2000).
Another mechanism for cancer cell killing by
CAPs is the induction of apoptosis by permeation of
mitochondrial membrane after internalization, release
of cytochrome c, leadind to caspase 9 and 3 activation
(Pardo et al. 2001). Both cationic and hydrophobic
amino acids play a role in the peptide permeation of
mitochondrial membranes (Horton et al. 2008). Alter-
natively, apoptosis may be induced by CAPs interaction
with cell death receptors, such as Fas ligand, leading to
caspase 8 activation. Interestingly, arginine, glycine and
asparagine, integrin homing domain (RGD)-conjugated
tachyplesin induced both pathways, suggesting that
some CAPs may have more than one effect on cancer
cells (Chen et al. 2001).
Protein glycosylation may alter the secondary
structure of a membrane-associated protein or peptide,
and altered glycosylation of membrane proteins is fre-
quently found in malignant cells. Moreover, differential
branching and sialic acid content of N-linked glycans
are associated with an increase in the net negative charge
in the membrane of many cancer cells. Interestingly,
peptide-glycosylation was associated with increased po-
tency of drosocin in vitro (McManus et al. 1999). It is
therefore likely that glycosylation of CAPs and/or can-
cer cell membrane proteins may influence the binding
affinity of some CAPs for the cancer cell.
CAPs may be used in combination with conven-
tional chemotherapeutic antitumor drugs in order to re-
duce effective doses, and thereby reduce harmful side-
effects frequently observed in treated patients. Cecropin
A, in combination with 5-fluorouracil and cytarabine,
showed a synergistic cytotoxic effect on human leukemia
cells (Hui et al. 2002).
Representative naturally occurring CAPs with anti-
tumor activities are depicted on Table I.
Peptides with antitumor activities have also been
produced and/or identified from other sources, such as
phage-, bacterial- and cell-display libraries. These pep-
tides can exhibit direct tumor cell cytotoxicity, act as
immunomodulators or as antiangiogenic factors. For a
review on these peptides, see Daffre et al. (2008).
A MODEL OF ANTITUMOR EFFECT OF A PEPTIDE
Gomesin is a CAP isolated from hemocytes of the un-
challenged Brazilian spider Acanthoscurria gomesia-
na. It is a hairpin-like two-stranded antiparallel β-sheet
structure formed by 18 amino acid residues and two post-
translational modifications, the N-terminal pyroglutamic
acid (Z) and the C-terminal amidated arginine residue
(Silva et al. 2000, Mandard et al. 2002; Table I). A
rigid conformation is maintained by two internal disul-
fide bridges formed by four cysteine residues, Cys2-15
and Cys6-11, together with six hydrogen bonds in the
central part of the molecule, as well as at each end of
the β-sheet (Mandard et al. 2002). The peptide is am-
phypathic, with a hydrophobic face (residues Leu5, Tyr7,
Val12 and Tyr14) and three hydrophilic regions contain-
ing positively charged and polar amino acids at the N-
terminus (Arg3 and Arg4), at the C-terminus (Arg16 and
Arg18) and within the canonical β-turn (Lys8, Gln9 and
Arg10) (Fazio et al. 2006). A representation of gomesin
is depicted on Figure 2.
As stated before, gomesin has a broad and strong
microbicidal activity. The peptide is active against Gram-
positive and Gram-negative bacteria, filamentous fungi,
yeast (Silva et al. 2000), Cryptococcus neoformans (Bar-
bosa et al. 2007) and parasites, such as Plasmodium fal-
ciparum and Plasmodium berghei (Moreira et al. 2007).
The antitumor activity of gomesin was tested in
vitro and in vivo (Rodrigues et al. 2008). Gomesin ex-
erted direct cytotoxic effects on murine and human tu-
mor cells in vitro. The estimated IC50 for the murinemelanoma cell line B16F10-Nex2 was 3.58 μM, and
was below 10 μM for human tumor cell lines (Fig. 3).
Human endothelial cells were also sensitive to gomesin
in vitro, with an IC50 of 5.30 μM. The cytotoxic effectwas time- and dose-dependent, and was not reversed af-
ter peptide removal. The β-hairpin structure and the am-
phipathicity of the peptide are important for antitumor
activity, since substitution of cysteine residues by serine
ones (eliminating one or both disulfide bridges), or dis-
ruption of the hydrophobic face (by substituting residues
Leu5 and/or Val12 by serine units) reduced or abolished
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TABLE INaturally occurring CAPs with antitumor activity.







In vitro Risso et al. 1998,












Moore et al. 1994,
Chan et al. 1998,
Winder et al. 1998,
Hui et al. 2002,
Ye et al. 2004,
Suttman et al. 2008
LL-37/hCAP-18 LLGDFFRKSKEKIGKEFKRIVQRIK-
DFLRNLVPRTES
Human In vitro Okumura et al. 2004,









Cruciani et al. 1991,
Soballe et al. 1995,
Takeshima et al. 2003,
Cruz-Chamoro et al. 2006,





Frog skin In vitro Kim et al. 2003,
Won et al. 2006
Aurein 1.2 GLFDIIKKIAESF Frog skin In vitro Rozek et al. 2000
Citropin 1.1 GLFDVIKKVASVIGGL Frog skin In vitro Doyle et al. 2003




Tosteson and Tosteson 1981,
Killion and Dunn 1986,
Saini et al. 1999,
Holle et al. 2003
Epinicidin-1 GFIFHIIKGLFHAGKMIHGLV Fish In vitro Lin et al. 2009









Human In vitro, In vivo
xenogeneic
model (HNP-1)
Lichtenstein et al. 1986,
Müller et al. 2002,
McKeown et al. 2006,
Xu et al. 2008
Bovine
Lactoferricin




Yoo et al. 1997a, b,
Eliassen et al. 2002,
Mader et al. 2005,
Eliassen et al. 2006






Li et al. 2000,
Chen et al. 2001,
Ouyang et al. 2002,
Chen et al. 2005,
Shi et al. 2006
Gomesin ZCRRLCYKQRCVTYCRGR Insect In vitro, In vivo
(local therapy)












In vitro Ohtake et al. 1999
*Amino acid (AA) sequences are given in one-letter code. Bold indicate Cys residues that form disulfide bonds.
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Fig. 2 – Schematic representation of gomesin. The molecule is formed by two antipar-
allel β-strands stabilized by 2 disulphide bridges (black lines) and 6 hydrogen bounds
(hatched lines). Gomesin contains a hydrophobic face and three hydrophilic regions.
Fig. 3 – Gomesin cytotoxicity in vitro against human tumor cells. Hu-
man melanoma (A2058) and cervical cancer (HeLa) cells were treated
in vitro with different concentrations of gomesin for 12 hours, and vi-
able cells were counted in presence of Trypan Blue. The percentage of
reduction of cell viability in relation to untreated cells is shown. The
melanoma A2058 was the most sensitive and HeLa the most resistant
cell line amongst all lineages studied (Rodrigues et al. 2008).
the cytotoxic effect. The enantiomer D-gomesin, syn-
thesized employing D-amino acids and containing both
disulfide bridges, was equally cytotoxic for tumor cells,
suggesting that chiral recognition is not required for the
antitumor effect (Rodrigues et al. 2008).
The peptide concentrates at the tumor cell mem-
brane and forms clusters, suggesting the formation of
pore structures. This putative pore formation by gomesin
at the cell surface, and consequent cell permeabiliza-
tion, caused (1) early morphological alterations, with
increased granularity and loss of cytoplasmic content;
(2) release of lactate dehydrogenase (LDH) in a dose-
dependent way; (3) partial inhibition of the respira-
tion-dependent proton gradient; (4) internalization of
immunoglobulins that reacted with tubulin filaments
and with nuclear histone H1 (monoclonal A4M). The
peptide did not induce apoptosis of tumor cells (Ro-
drigues et al. 2008).
Interestingly, the monoclonal antibody (mAb) A4M
is an IgM that recognizes nuclear histone H1 in B16F10-
Nex2 murine melanoma cells, but is not cytotoxic to the
intact tumor cell (A.S. Dobroff et al., unpublished re-
sults). After treatment with low doses of gomesin, how-
ever, the mAb A4M was internalized in B16F10-Nex2
cells and showed additive cytotoxic activity in vitro.
Therefore, gomesin at low concentrations could facili-
tate the penetration of drugs inside tumor cells, poten-
tially reducing toxic doses and allowing penetration of
molecules that are not directly cytotoxic to cells with
intact membranes.
More importantly, topical in vivo treatment with
gomesin significantly delayed subcutaneous murine
melanoma development and significantly increased the
survival of animals with tumors below the allowed max-
imal size limit. Male mice with established subcuta-
neous B16F10-Nex2 tumors (4–10 mm3) were treated
topically three times a week with individual doses of
4 μg of gomesin incorporated in 20 mg of an anionic,
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oil-in-water cream. This effect can be explained by the
direct effect of gomesin on tumor cells, but also by an
effect on tumor neoangiogenesis, since endothelial cells
were sensitive to low concentrations of the peptide.
Repeated topical applications of gomesin did not affect
the peripheral healthy skin of treated mice (Rodrigues et
al. 2008).
Some patients may develop extensive, confluent re-
gional metastases near the primary nodular melanoma.
In these cases, surgical excision or radiotherapy are un-
suitable, and topical treatment is a preferred alternative.
Some topical treatments have indeed being used ten-
tatively, but only partial responses were obtained with
5-aminolevulinic acid photodynamic therapy (Wolf et
al. 1993), imiquimod (Steinmann et al. 2000, Hesling et
al. 2004), dinitrochlorobenzene (Malek-Mansour 1973,
Illig et al. 1984, von Nida and Quirk 2003), and diphen-
cyprone (Damian and Thompson 2007). Gomesin could
be an alternative for treatment of these patients and
eventually also patients with other skin cancers.
PERSPECTIVES
Peptides used in protective protocols against pro- and
eukaryotic cells, including fungi and tumor cells, can
act directly on target cells or will elicit an immune re-
sponse that may be effective to control infections and
tumor development. Peptides allow structural changes
to incorporate protective substitutions, chiral derivatives,
non-natural amino acids and other modifications aiming
at increased stability, efficiency and resistance to prote-
olysis. In this sense, they are much more drug-like than
recombinant proteins. A great number of peptide se-
quences with biological activity is now recognized, and
the finding that fragments of immunoglobulin variable
chains have increased frequency of bioactivity opens a
broad field of investigation. Peptide-based vaccines are
now in development for various pathologies including
cancer (Purcell et al. 2007). The possibility of chemi-
cal synthesis of a limitless variety of peptide sequences
and derivatives poses the question of how many more
reagents can be produced compared to our capacity to
test them in different biological systems. The use of
promiscuous peptides for vaccination of a genetically
heterogeneous population is another aspect that has to be
considered. Remarkably, the P10 from gp43 is a good
vaccine candidate being presented by most Caucasian
HLA-DR molecules, and being able to protect against
massive P. brasiliensis infection in normal and immuno-
suppressed mice. The combination of chemotherapy and
P10 vaccination is therefore a very promising strategy
to treat human PCM. Antitumor peptides for systemic
and topical treatment are additional tools that can be
largely developed as adjuvants of conventional treatment.
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RESUMO
Peptídeos são moléculas particularmente reativas produzidas
por uma grande variedade de espécies, aptos a exercer um
número de funções em organismos uni- e multicelulares como
mediadores, agonistas e substâncias regulatórias. Alguns de-
les exercem efeitos citotóxicos em células outras das que os
produzem, e podem ter um papel controlando subpopulações
e protegendo certas espécies ou tipos celulares. No presente,
focalizamos peptídeos antifúngicos e antitumorais e discutimos
alguns modelos nos quais seqüências específicas e estruturas
exercem efeitos inibitórios diretos ou estimulam uma respos-
ta imune protetora. O peptídeo letal (“killer”), deduzido de
um anticorpo anti-idiotípico, com várias atividades antimicro-
bianas bem como outros peptídeos derivados de imunoglobu-
linas com atividades citotóxicas incluindo efeitos antitumorais
são modelos estudados in vitro e in vivo. O peptídeo P10 da
gp43 de P. brasiliensis e a perspectiva de vacina contra a para-
coccidioidomicose é outro tópico ilustrando o efeito protetor in
vivo contra um fungo patogênico. Peptídeos antimicrobianos
catiônicos com atividades antitumorais são os principais re-
vistos aqui. O tratamento local do melanoma murino com o
peptídeo gomesina é outro modelo estudado na Unidade de
Oncologia Experimental (UNONEX) da UNIFESP.
Palavras-chave: peptídeos bioativos, Paracoccidioides brasi-
liensis, células tumorais, peptídeo letal, melanoma, apoptose.
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